What is Cinacalcet?
Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of end-stage renal disease. Cinacalcet, sold under the brand name Sensipar among others. Cinacalcet is used alone or with other medications to treat secondary hyperparathyroidism. Commonly reported side effects of cinacalcet include: decreased plasma testosterone, diarrhea, dizziness, myalgia, nausea, vomiting, and hypoparathyroidism.
The market study is broken down by Type (30 mg Tablets and 60 mg Tablets), by Application (Hospitals, Medical Research Center, Pharmaceutical Factory and Others) and major geographies with country level break-up.
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that Players from United States and Indian will contribute to the maximum growth of Global Cinacalcet market throughout the predicted period.
Amgen Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Genzyme Corporation (Sanofi) (United States), AbbVie Inc. (United States), Cipla Inc. (India), Dr. Reddy’s Laboratories Ltd. (India), OPKO Health, Inc. (United States), Mylan (United States), Aurobindo Pharma (India) and Sun Pharmaceutical (India) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Cinacalcet market by Type, Application and Region.
On the basis of geography, the market of Cinacalcet has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Cinacalcet market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. and Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD).
- Increasing awareness about hyperparathyroidism in physicians, as well as clinical specialists, have improved the treatment regimen for its management
- Reduction in associated complications for the management of hyperparathyroidism
- Increasing prevalence of chronic kidney disease among geriatric population as well as general population
- Rising cases of renal disease and increasing patient pool will have a significant impact on the market
- Increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market
- The increasing government initiatives for improvising secondary hyperparathyroidism management
- Side effect such as nausea, vomiting, diarrhoea, etc. associated with the medication
- High competition among established players
Key Target AudienceCinacalcet Producers, Cinacalcet Supplier, Research and Development Institutes, Potential Investors, Hospitals, Regulatory Bodies and Others
About ApproachDuring this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase